

Specialty Guideline Management

Joenja

Products Referenced by this Document

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-the-counter (OTC) products are not included unless otherwise stated.

Brand Name	Generic Name
Joenja	leniolisib

Indications

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

FDA-approved Indications

Joenja is indicated for the treatment of activated phosphoinositide 3-kinase delta (PI3K δ) syndrome (APDS) in adults and pediatric patients 12 years of age and older.

All other indications are considered experimental/investigational and not medically necessary.

Documentation

Submission of the following information is necessary to initiate the prior authorization review:

- Testing or analysis confirming a mutation of either the PIK3CD or PIK3R1 gene.
- Medical record documentation confirming the member demonstrates clinical manifestations of the disease (e.g., history of repeated oto-sino-pulmonary infections, lymphoproliferation, autoimmunity [e.g., cytopenia], enteropathy, organ dysfunction [e.g., lung, liver]).

Prescriber Specialties

This medication must be prescribed by or in consultation with an immunologist or a physician who specializes in the treatment of APDS.

Coverage Criteria

Activated Phosphoinositide 3-kinase Delta (PI3K δ) Syndrome (APDS)

Authorization of 6 months may be granted for treatment of APDS when all of the following criteria are met:

- Member's diagnosis was confirmed by genetic testing demonstrating variant in either the PIK3CD or PIK3R1 gene.
- Member has clinical manifestations of disease (e.g., history of repeated oto-sino-pulmonary infections, lymphoproliferation, autoimmunity [e.g., cytopenia], enteropathy, organ dysfunction [e.g., lung, liver]).
- Member is 12 years of age or older and weighs greater than or equal to 45 kg.

Continuation of Therapy

Authorization of 12 months may be granted for continued treatment in all members (including new members) who are currently receiving the requested medication and who are experiencing benefit from therapy as evidenced by disease stability or disease improvement.

References

1. Joenja [package insert]. Warren, NJ: Pharming Healthcare Inc.; March 2023.
2. Rao VK, Webster S, Šedivá A, et al. A randomized, placebo-controlled phase 3 trial of the PI3K δ inhibitor leniolisib for activated PI3K δ syndrome. *Blood*. 2023;141(9):971-983. doi:10.1182/blood.2022018546